Skip to main content

Advertisement

Table 3 Background characteristics of patients with total cohort, group A and group B

From: Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer

  Total Group A (non-metastatic group) Group B (metastatic group)
Number of patients 167 42 125
Age (median) 64.0 65.0 63.0
Gender (%)    
Male 124 (74.3) 29 (69.0) 95 (76.0)
Female 43 (15.7) 13 (31.0) 30 (24.0)
ECOG PS (%)    
0 79 (47.3) 33 (78.6) 46 (36.8)
1 86 (51.5) 9 (21.4) 77 (61.6)
2 2 (1.2) 0 (0.0) 2 (1.6)
Histological type (%)    
Intestinal type 60 (35.9) 10 (23.8) 50 (40.0)
Diffuse type 107 (64.1) 36 (76.2) 71 (60.0)
T-stage    
T1 9 (5.4) 7 (16.7) 2 (1.6)
T2 34 (20.4) 9 (21.4) 25 (20.0)
T3 101 (60.5) 22 (52.4) 79 (63.2)
T4 23 (13.8) 4 (9.5) 19 (15.2)
N-stage    
Nx 4 (2.4) 2 (4.8) 2 (1.6)
N0 22 (13.2) 12 (28.6) 10 (8.0)
N1 56 (33.5) 16 (38.1) 40 (32.0)
N2 53 (31.7) 9 (21.4) 44 (35.2)
N3 32 (19.2) 3 (19.2) 29 (23.2)
Metastatic lesion (%)    
1 135* (80.8) 40* (95.2) 95 (76.0)
2 32 (19.2) 2 (4.8) 30 (24.0)
Metastatic site (%)    
Lymph node 92* (55.1) 19* (45.2) 73 (58.4)
Liver 34 (20.3) 2** (4.8) 32 (25.6)
Lung 8 (4.8) 0 (0.0) 8 (6.4)
Peritoneal dissemination 43 (25.7) 3** (7.1) 40 (32.0)
Other 6 (3.6) 0 (0.0) 6 (4.8)
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status. Staging (TNM classification) is diagnosed by Japanese Classification of Gastric Carcinoma (The 13th Edition) , *including metastasis to regional lymph nodes. **resectable lesion.